Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint inhibitors to treat cutaneous malignancies
Dulce M. Barrios, H. Mytrang, Gregory S. Phillips, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 5, pp. 1239-1253
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 225
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
Alexander J. Stratigos, Aleksandar Sekulić, Ketty Peris, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 6, pp. 848-857
Open Access | Times Cited: 224
Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma
Haozhen Lv, Xiao Liu, Xuanhao Zeng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 184
New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma
Alessia Villani, Luca Potestio, Gabriella Fabbrocini, et al.
Advances in Therapy (2022) Vol. 39, Iss. 3, pp. 1164-1178
Open Access | Times Cited: 53
Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
Yi-Shan Teng, Sebastian Yu
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6805-6819
Open Access | Times Cited: 24
Roles and therapeutic implications of m6A modification in cancer immunotherapy
Juan Pan, Tuxiong Huang, Zhenjun Deng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
An antitumor arabinan from Glehnia littoralis activates immunity and inhibits angiogenesis
Wenhui Liu, Kexin Li, Han Zhang, et al.
International Journal of Biological Macromolecules (2024) Vol. 263, pp. 130242-130242
Closed Access | Times Cited: 8
CLINICAL DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS
Jianxin Wang, Qi Chen, Qi Shan, et al.
Cancer Letters (2025), pp. 217616-217616
Closed Access | Times Cited: 1
Multi-omics analysis elucidates the relationship between intratumor microbiome and host immune heterogeneity in breast cancer
Jia Li, Yu Zhang, Yifan Cai, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 7
Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma
Enrico Zelin, Iris Zalaudek, Marina Agozzino, et al.
Current Treatment Options in Oncology (2021) Vol. 22, Iss. 4
Open Access | Times Cited: 37
Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response
Enrico Zelin, Carlo Alberto Maronese, Arianna Dri, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 12, pp. 3364-3364
Open Access | Times Cited: 27
The integration of single-cell sequencing, TCGA, and GEO data analysis revealed that PRRT3-AS1 is a biomarker and therapeutic target of SKCM
Wancong Zhang, Xuqi Xie, Zijian Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Development and experimental validation of a machine learning-based disulfidptosis-related ferroptosis score for hepatocellular carcinoma
Cong Zhang, Tiantian Xu, Kun Ji, et al.
APOPTOSIS (2023) Vol. 29, Iss. 1-2, pp. 103-120
Closed Access | Times Cited: 16
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma
Alessia Villani, Sonia Sofía Ocampo‐Garza, Luca Potestio, et al.
Expert Opinion on Drug Safety (2021) Vol. 21, Iss. 1, pp. 21-29
Closed Access | Times Cited: 28
Melatonin as a Repurposed Drug for Melanoma Treatment
Rachana Pathipaka, Anita Thyagarajan, Ravi P. Sahu
Medical Sciences (2023) Vol. 11, Iss. 1, pp. 9-9
Open Access | Times Cited: 11
Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital
Gloria Juan‐Carpena, Natividad Martínez-Banaclocha, Juan Carlos Palazón Cabanes, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv42023-adv42023
Open Access
Lichen Sclerosus in Cancer Patients
Amaris Geisler, S. K. Jain, Kara Long Roche, et al.
Journal of Lower Genital Tract Disease (2025)
Closed Access
The Importance of Timing in Immunotherapy: A Systematic Review
Stephanie Nagy, Atif M. Hussein, Marc M Kesselman
Cureus (2025)
Open Access
Advances in Targeting Cutaneous Melanoma
Dimitri Kasakovski, Marina Skrygan, Thilo Gambichler, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2090-2090
Open Access | Times Cited: 24
Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment
Clio Dessinioti, Alexander J. Stratigos
Dermatology Practical & Conceptual (2023), pp. e2023252-e2023252
Open Access | Times Cited: 10
Emerging immunologic approaches as cancer anti-angiogenic therapies
Mohammadreza Azimi, Mahdokht Sadat Manavi, Maral Afshinpour, et al.
Clinical & Translational Oncology (2024)
Closed Access | Times Cited: 3
An Updated Review of Immune Checkpoint Inhibitors in Cutaneous Oncology: Beyond Melanoma
James P. Pham, Ramon Staeger, Anthony M. Joshua, et al.
European Journal of Cancer (2024) Vol. 214, pp. 115121-115121
Open Access | Times Cited: 3
Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma
Isabelle Poizot‐Martin, Sylvie Brégigeon, Romain Palich, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 986-986
Open Access | Times Cited: 15
Therapeutic Perspectives in the Systemic Treatment of Kaposi’s Sarcoma
Marc‐Antoine Valantin, Léna Royston, Maxime Hentzien, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 484-484
Open Access | Times Cited: 14
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
Lakshmi Rajdev, Chia-Ching J. Wang, Himanshu Joshi, et al.
Cancer (2023) Vol. 130, Iss. 6, pp. 985-994
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top